Quick Answer
Evofem Biosciences, Inc. reported Net Income Loss of -$8.86 million for the year ending 2024.
- Evofem Biosciences, Inc. showed a decrease of -116.7% in Net Income Loss from 2023 to 2024.
- This data is from Evofem Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2013 to 2024 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2013 to 2024), Evofem Biosciences, Inc.'s Net Income Loss has grown by 41.0%.
- Historical annual values: Fiscal year 2024: -$8.86 million | Fiscal year 2023: $52.98 million | Fiscal year 2022: -$76.70 million | Fiscal year 2021: -$205.19 million | Fiscal year 2020: -$142.31 million | Fiscal year 2019: -$80.03 million | Fiscal year 2018: -$125.71 million | Fiscal year 2017: -$105.31 million | Fiscal year 2016: -$13.02 million | Fiscal year 2015: -$43.16 million | Fiscal year 2014: -$10.82 million | Fiscal year 2013: -$15.02 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: